A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer

OBJECTIVE: Ten percent of ovarian cancer is attributed to hereditary syndromes, most commonly to mutations in the BRCA1 or BRCA2 genes. These cancers are characterized by a prolonged sensitivity to platinum agents in spite of presentation at advanced stages. We hypothesized that women with BRCA-asso...

詳細記述

保存先:
書誌詳細
主要な著者: Adams, Sarah F., Marsh, Evelyn B., Elmasri, Wafic, Halberstadt, Steffanie, VanDecker, Stephanie, Sammel, Mary D., Bradbury, Angela R., Daly, Mary, Karlan, Beth, Rubin, Stephen C.
フォーマット: Artigo
言語:Inglês
出版事項: 2011
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3260049/
https://ncbi.nlm.nih.gov/pubmed/21945552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2011.08.032
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料